1(8)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma Journal Article
| Authors: | Mahajan, S.; Barker, C. A.; Mauguen, A.; D’Angelo, S. P.; Yeh, R.; Pandit-Taskar, N. |
| Article Title: | 1(8)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma |
| Abstract: | To investigate diagnostic and prognostic value of 18F-FDG PET/CT for surveillance imaging in patients treated for Stage III Merkel cell carcinoma (MCC). Methods: This retrospective study included 61 consecutive stage III MCC patients, who were clinically asymptomatic and underwent surveillance FDG-PET/CT. Findings were correlated with either pathology and/or clinical/imaging follow-up. Median follow-up period was 4.8 years. Statistical analyses were performed. Results: FDG-PET/CT detected unsuspected recurrences in 33% patients (20/61) with lesion-based sensitivity, specificity, and accuracy of 92%, 93%, and 93%, respectively. Mean±SD SUV for malignant and benign lesions was 7.5±3.9 and 3.8±2.0, respectively. Unknown distant metastases, as first recurrence site, were noted in 12 of 61 patients. Those with positive disease on FDG-PET/CT within one year of definitive treatment had relatively worse overall survival (p<0.0001). After adjustment on stage, risk of death increased with higher SUVmax (HR for one unit=1.17;p=0.006) and with a higher number of positive lesions on FDG-PET/CT (HR for one additional lesion=1.60;p<0.001). Conclusion: Post-definitive treatment surveillance FDG-PET/CT scan detects unsuspected recurrences and has prognostic value. Inclusion of FDG-PET/CT within the first 6 months after definitive treatment would be appropriate for surveillance and early detection of recurrence. Our data merits further studies to evaluate the prognostic implications. © 2022 Society of Nuclear Medicine Inc.. All rights reserved. |
| Keywords: | adult; aged; retrospective studies; major clinical study; cancer staging; positron emission tomography; diagnostic accuracy; sensitivity and specificity; radiopharmaceuticals; skin neoplasms; recurrence; diagnostic imaging; retrospective study; confidence interval; skin tumor; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; radiopharmaceutical agent; recurrent disease; merkel cell carcinoma; carcinoma, merkel cell; fdg pet/ct; predictive value; surveillance; disease surveillance; diagnostic test accuracy study; procedures; cancer prognosis; humans; prognosis; human; male; female; article; positron emission tomography-computed tomography; positron emission tomography computed tomography |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 63 |
| Issue: | 6 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2022-06-01 |
| Start Page: | 906 |
| End Page: | 911 |
| Language: | English |
| DOI: | 10.2967/jnumed.121.262882 |
| PUBMED: | 34620729 |
| PROVIDER: | scopus |
| PMCID: | PMC9157731 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work